[1]李晓丽,胡陇娟.子宫内膜癌组织中长链非编码RNA ZEB1-AS1的表达与临床特征及对化疗药物耐药性研究[J].现代检验医学杂志,2019,34(04):35-39.[doi:10.3969/j.issn.1671-7414.2019.04.009]
　LI Xiao-li,HU Long-juan.Research on Expression and Clinical Characteristics of Long-Chain Non-Coding RNA ZEB1-AS1 in Endometrial Carcinoma and Resistance to Chemotherapy Drugs[J].Journal of Modern Laboratory Medicine,2019,34(04):35-39.[doi:10.3969/j.issn.1671-7414.2019.04.009]
点击复制

子宫内膜癌组织中长链非编码RNA ZEB1-AS1的表达与临床特征及对化疗药物耐药性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年04期
页码:
35-39
栏目:
论著
出版日期:
2019-08-20

文章信息/Info

Title:
Research on Expression and Clinical Characteristics of Long-Chain Non-Coding RNA ZEB1-AS1 in Endometrial Carcinoma and Resistance to Chemotherapy Drugs
文章编号:
1671-7414(2019)04-035-05
作者:
李晓丽1; 胡陇娟2
(1.宝鸡市妇幼保健院妇科,陕西宝鸡 721000; 2.宝鸡高新人民医院产科,陕西宝鸡 721013)
Author(s):
LI Xiao-li1; HU Long-juan2
(1.Department of Gynaecology,Baoji Maternal and Child Health Care Hospital,Shaanxi Baoji721000,China; 2.Department of Obstetrics,Baoji High-Tech People's Hospital,ShaanxiBaoji 721013,China)
关键词:
子宫内膜癌;  化疗;  耐药;  ZEB1-AS1
分类号:
R737.33; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.04.009
文献标志码:
A
摘要:
目的 探讨长链非编码RNA(long noncoding RNA,lnc RNA)ZEB1-AS1在子宫内膜癌化疗耐药中的作用。方法 收集2013年1月～2017年12月入住宝鸡市妇幼保健院妇科的177例子宫内膜癌患者的临床特征,通过实时荧光定量PCR(real-time PCR,RT-PCR)检测lnc RNA ZEB1-AS1的表达,分析lnc RNA ZEB1-AS1的表达量与临床特征之间的关联。采用CCK-8实验检测lnc RNA ZEB1-AS1对子宫内膜癌细胞增殖的影响,通过化疗药物干预检测其对化疗药物敏感度的影响。结果 lnc RNA ZEB1-AS1在子宫内膜癌中高表达(0.006 0±0.020 0 vs 0.003 0±0.014 1,P=0.035),且其高表达与低表达在子宫内膜癌患者临床分期(χ2=14.293,P=0.001)、是否化疗(χ2=6.049,P=0.019)、是否原位癌(χ2=8.245,P=0.041)、是否淋巴结转移(χ2=10.427,P=0.005)、是否远端转移(χ2=20.229,P<0.001)以及HPV阴阳性(χ2=12.710,P=0.001)之间的差异均具有统计学意义。过表达lnc RNA ZEB1-AS1能促进子宫内膜癌细胞增殖(P<0.05),过表达lnc RNA ZEB1-AS1后子宫内膜癌细胞对化疗药物的敏感度降低(P<0.05)。结论 lnc RNA ZEB1-AS1在子宫内膜癌中高表达,且干扰lnc RNA ZEB1-AS1的表达能抑制子宫内膜癌细胞增殖、转移和侵袭,并增加子宫内膜癌细胞对化疗药物的敏感度。
Abstract:
Objective To detectthe effect of long noncoding RNA(lnc RNA)ZEB1-AS1 on the sensibility of chemotherapy on endometrial cancer.Methods The clinical characteristics of 177 patients with endometrial cancer admitted to Baoji Maternal andChild Health Care Hospital from January 2013 to December 2017 were collected.The expression of lnc RNA ZEB1-AS1 was detected by real-time quantitative PCR(RT--PCR).The correlation between the expression of lnc RNA ZEB1-AS1 and clinical characteristics was analyzed.The effect of ZEB1-AS1 on the proliferation of endometrial cancer cells was detected by CCK-8 assay and chemotherapeutic intervention on the sensitivity of chemotherapeutic drugs was tested.Results lnc RNA ZEB1-AS1 was up-regulated in endometrial cancer tissues(0.014 5±0.021 3 vs 0.002 0±0.003 1,P=0.034).The difference between up regulated group and down regulated group with endometrial cancer patients were statistically significant in clinical stage of the patients(χ2=14.293,P=0.001),chemotherapy(χ2=6.049,P=0.019),T stage(χ2=8.245,P=0.041),N stage(χ2=10.427,P=0.005),M stage(χ2=20.229,P<0.001),and HPV infection(χ2=12.710,P=0.001).Over expression of lnc RNA ZEB1-AS1 promotes the proliferation of cancer cell line(P<0.05),and over expression of lnc RNA ZEB1-AS1 decreased the sensibility to chemotherapy medicine of cancer cell line(P<0.05).Conclusionlnc RNA ZEB1-AS1 was up regulated in endometrial cancer,over expression of lnc RNA ZEB1-AS1 promotes the proliferation,migration,and invasion abilities of brain tumor cell line,decreased the sensibility of brain tumor cellline.

参考文献/References:

[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer sta-tistics,2019[J].CA Cancer J Clin,2019,69(1):7-34. [2] CHEN Wanqing,XIA Changfa,ZHENG Rongshong,et al.Disparities by province,age and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China:a comparative risk assessment[J].The Lancet Global Health,2019,7(2):e257-e269. [3] ALLEMANI C,MATSUDA T,CARLO V D,et al.Global surveillance of trends incancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].The Lancet,2018,391(10125):1023-1075. [4] KASSEBAUM N J,BERTOZZIVLLA A,COGGESHALL M S,et al.Global,regional and national levels and causes of maternal mortality during 1990-2013:a systematic analysis for the global burden of disease study 2013[J].Lancet,2014,384(9947):980-1004. [5] World Health Organization.World health statistics 20 17:monitoring health for the SDGS,sustainable development goals[M].Geneva:World Health Organization,2017. [6] 郑福利,党淼,张淼芳,等.子宫内膜癌组织中趋化因子CXCL12及其受体CXCR4表达水平研究[J].现代检验医学杂志,2015,30(4):21-23,27. ZHENG Fuli,DANG Miao,ZHANG Miaofang,et al.Expression of chemokine CXCL12 and its receptor CXCR4 in endometrial carcinoma tissues[J].Journal of Modern Laboratory Medicine,2015,30(4):21-23,27. [7] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28. ZHENG Rongshou,SUN Kexin,ZHANG Siwei,et al.Report of cancer epidemiology in China,2015[J].Chin J Oncol,2019,41(1):19-28. [8] 李玲,罗雅文,何霞,等.子宫内膜癌患者BMI与血清HE4,CA125联合检测的诊断价值[J].现代检验医学杂志,2018,33(5):91-94. LI Ling,LUO Yawen,HE Xia,et al.Diagnostic value of combined detection of body mass index and serum HE4,CA125 in patients with endometrial carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(5):91-94. [9] 陈万青,李贺,孙可欣,等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志,2018,40(1):5-13. CHEN Wanqing,LI He,SUN Kexin,et al.Report of cancer incidence and mortality in China,2014[J].Chin J Oncol,2018,40(1):5-13. [10] SUN Yuanyuan,WANG Yanhong,LI Mengmeng,et al.Long-term trends of liver cancer mortality by gender in urban and rural areas in China:an age-period-cohort analysis[J].BMJ Open,2018,8(2):e020490. [11] 吴海芳,孟祥玉,许恒毅,等.Ⅱ型子宫内膜癌相关基因突变及靶向治疗研究进展[J].基础医学与临床,2019,39(2):277-230. WU Haifang,MENG Xiangyu,XU Hengyi,et al.Research progress on gene mutations and targeted therapy of type Ⅱ endometrial carcinoma[J].Basic & Clinical Medicine,2019,39(2):277-230. [12] 弓翠萍,白爱峰,常捷芳.分子靶向治疗联合化疗对晚期子宫内膜癌的临床疗效[J].临床医学研究与实践,2018,3(31):32-33. GONG Cuiping,BAI Aifeng,CHANG Jiefang.Clinical effect of molecular targeted therapy combined with chemotherapy on advanced endometrial carcinoma[J].Clinical Research and Practice,2018,3(31):32-33. [13] 余昌,岳成山,王会霞,等.Ⅲ期子宫内膜癌患者调强放疗联合化疗治疗的疗效及不良反应分析[J].实用癌症杂志,2019,34(1):145-147. YU Chang,YUE Chengshan,WANG Huixia,et al.Clinical efficacy and adversereactions of patients with stage Ⅲ endometrial cancer with TP chemotherapy combined with intensity modulated radiation therapy[J].The Practical Journal ofCancer,2019,34(1):145-147. [14] LEE Y C,LHEUREUX S,OZA A M.Treatment strategies for endometrial cancer:current practice and perspective[J].Curr Opin Obstet Gynecol,2017,29(1):47-58. [15] 陈万青,郑荣寿,张思维,等.2013年中国老年人群恶性肿瘤发病和死亡分析[J].中华肿瘤杂志,2017,39(2):60-66. CHEN Wanqing,ZHENG Rongshou,ZHANG Siwei,et al.Analysis of cancer incidence and mortality in elderly population in China,2013[J].Chin J Oncol,2017,39(2):60-66. [16] CHANG Y S,HUANG H D,YEH K T,et al.Identification of novel mutationsin endometrial cancer patients by whole-exome sequencing[J].Int J Oncol,2017,50(5):1778-1784. [17] 饶建,林秀欣,李春鸣.晚期子宫内膜癌术后同期放化疗与序贯放化疗的疗效对比[J].现代诊断与治疗,2018,29(13):2029-2032. RAO Jian,LIN Xiuxin,LI Chunming.Evaluation of concurrent chemoradiotherapy and sequential chemoradiotherapy for advanced endometrial carcinoma[J].Modern Diagnosis & Treatment,2018,29(13):2029-2032. [18] 白盈盈,朱光旭,潘兴华.长链非编码RNA对结直肠癌潜在诊断价值的研究进展[J].现代检验医学杂志,2018,33(1):161-164. BAI Yingying,ZHU Guangxu,PAN Xinghua.Advances in the potential diagnostic value of long non-coding RNA for colorectal cancer[J].Journal of Modern Laboratory Medicine,2018,33(1):161-164. [19] 王栋,金岚,王今,等.MALAT1在结直肠癌组织细胞中的表达及对化疗敏感性的影响[J].中国医药导报,2016,13(32):12-16. WANG Dong,JIN Lan,WANG Jin,et al.Expression of MALAT1 in colorectal cancer tissue cells and its influence for the chemotherapy sensitivity[J].China Medical Herald,2016,13(32):12-16. [20] 陈天天,王文锐,陈素莲,等.乳腺癌紫杉醇耐药细胞中lncRNA和mRNA表达谱筛选[J].蚌埠医学院学报,2018,43(10):1322-1328. CHEN Tiantian,WANG Wenrui,CHEN Sulian,et al.Screening of lncRNA and mRNA expression profiles in paclitaxel-induced breast cancer MCF-7 resistant cells[J].J Bengbu Med Coll,2018,43(10):1322-1328. [21] 杨野梵,马中华,王科明.长链非编码RNA调控结直肠癌耐药的研究进展[J].临床肿瘤学杂志,2018,23(5):458-462. YANG Yefan,MA Zhonghua,WANG Keming.Progression of long chain non codingRNA in the regulation of drug resistance in colorectal cancer[J].Chinese Clinnical Oncology,2018,23(5):458-462. [22] MA Minghui,AN Jiaxiang,ZHANG Cheng,et al.ZEB1-AS1 initiates a miRNA-mediated ceRNA network to facilitate gastric cancer progression[J].CancerCell Int,2019,19(1):27. [23] JIN Jianjun,WANG Huanqin,SI Jiming,et al.ZEB1-AS1 is associated with poor prognosis in non-small-cell lung cancer and influences cell migration and apoptosis by repressing id1[J].Clin Sci(Lond),2019,133(2):381-392. [24] ZHANG Liming,ZHANG Lanfang,GUO Xiaohe,et al.Downregulation of miR-335-5p by long noncoding RNA ZEB1-AS1 in gastric cancer promotes tumor proliferation and invasion[J].DNA Cell Biol,2018,31(7):46-52. [25] LIU X J,LI S L,LI J S,et al.Long non-coding RNA ZEB1-AS1 is associated with poor prognosis in gastric cancer and promotes cancer cell metastasis[J].Eur Rev Med Pharmacol Sci,2018,22(9):2624-2630. [26] WU Ying,DING Ming,WEI Shuzhen,et al.The prognostic value of long noncoding RNA ZEB1-AS1 on clinical outcomes in human cancer[J].J Cancer,2018,9(20):3690-3698. [27] WANG Qiong,ZHANG Ruirui,LIU Dandan.Long non-coding RNA ZEB1-AS1 indicates poor prognosis and promotes melanoma progression through targeting miR-1224-5p[J].Exp Ther Med,2019,17(1):857-862. [28] WANG Juan,PANG Jian,LI Huiling,et al.LncRNA ZEB1-AS1 was suppressed by p53 for renal fibrosis in diabetic nephropathy[J].Mol Ther Nucleic Acids,2018,12(2):741-750. [29] QU Ruize,CHEN Xiaomin,ZHANG Chao.LncRNA ZEB1-AS1/miR-409-3p/ZEB1 feedback loop is involved in the progression of non-small cell lung cancer[J].Biochem Biophys Res Commun,2018,507(4):450-456. [30] NI Ying,FANG Jian,ZHU Linqi,et al.The significant prognostic value of ZEB1-AS1 up-regulation in patients with cancer[J].J Cancer,2018,9(14):2502-2509. [31] WEI N,WEI H,ZHANG H.Long non-coding RNA ZEB1-AS1 promotes glioma cell proliferation,migration and invasion through regulating miR-577[J].EurRev Med Pharmacol Sci,2018,22(10):3085-3093.

相似文献/References:

[1]张 磊,李 娟,王金华,等.实体肿瘤化疗患者使用粒细胞集落刺激因子对外周血中性粒细胞形态参数变化的影响[J].现代检验医学杂志,2017,32(06):128.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　ZHANG Lei,LI Juan,WANG Jin-hua,et al.Changes of Neutrophil Morphological Parameters in Peripheral Blood of Patients with Solid Tumor Treated with Granulocyte Colony Stimulating Factor[J].Journal of Modern Laboratory Medicine,2017,32(04):128.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[2]李 玲a,罗雅文a,何 霞a,等.子宫内膜癌患者BMI与血清HE4,CA125联合检测的诊断价值[J].现代检验医学杂志,2018,33(05):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
　LI Linga,LUO Ya-wena,HE Xiaa,et al.Diagnostic Value of Combined Detection of Body Mass Index and Serum HE4,CA125 in Patients with Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(04):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
[3]曹 玲.长链非编码RNA ZEB1-AS1在儿童脑肿瘤中表达及对化疗药物敏感性影响的实验研究[J].现代检验医学杂志,2019,34(05):84.[doi:10.3969/j.issn.1671-7414.2019.05.021]
　CAO Ling.Experimental Study on the Expression Pattern of Long Non-Coding RNA ZEB1-AS1 and Its Effect on the Resistance of Chemotherapy on Childhood Brain Tumor[J].Journal of Modern Laboratory Medicine,2019,34(04):84.[doi:10.3969/j.issn.1671-7414.2019.05.021]
[4]王娟,刘鑫,席稳燕.HMMR-AS1 在子宫内膜癌化疗耐药中的作用[J].现代检验医学杂志,2020,35(05):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
　WANG Juan,LIU Xin,XI Wen-yan.Effect of HMMR-AS1 on the Chemotherapy-Resistance of Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2020,35(04):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
[5]李功娟,张治洋,樊阳阳.FEZF1-AS1在子宫内膜癌中的表达及其与患者临床特征的相关性[J].现代检验医学杂志,2021,36(01):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
　LI Gong-juan,ZHANG Zhi-yang,FAN Yang-yang.Expression of FEZF1-AS1 in Endometrial Carcinoma and Its Correlation with Clinical Characteristics of Patients[J].Journal of Modern Laboratory Medicine,2021,36(04):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
[6]陈丽华,朱婕曼,刘玉凤,等.子宫内膜癌组织中血管紧张素~1-7及线粒体组装受体水平表达与临床病理特征的相关性[J].现代检验医学杂志,2021,36(02):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
　CHEN Li-hua,ZHU Jie-man,LIU Yu-feng,et al.Correlation between the Expression of Angiotensin (1-7) and Mitochondrial Assembled Receptors and Clinicopathological Characteristics in Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2021,36(04):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
[7]陈晓宇,曾庆维,陈红林,等.子宫内膜癌组织中miR-3188和mTOR表达量与预后的相关性研究[J].现代检验医学杂志,2021,36(06):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
　CHEN Xiao-yu,ZENG Qing-wei,CHEN Hong-lin,et al.Study on the Correlation between the Expression Levels of miR-3188 and mTOR in Endometrial Cancer and the Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(04):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
[8]刘静雅,张海亮,李宝平,等.长链非编码 RNA SNHG1在子宫内膜癌中的表达及调控 PI3K/AKT信号通路的研究[J].现代检验医学杂志,2022,37(01):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
　LIU Jing-ya,ZHANG Hai-liang,LI Bao-ping,et al.Expression of Long Non-coding RNA SNHG1 in Endometrial Carcinoma and Its Regulation of PI3K/AKT Signaling Pathway[J].Journal of Modern Laboratory Medicine,2022,37(04):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
[9]彭 浩,张印星,谢 环.长链非编码RNA CDKN2BAS 在子宫内膜癌组织表达及其生物学功能研究[J].现代检验医学杂志,2023,38(03):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
　PENG Hao,ZHANG Yin-xing,XIE Huan.Expression and Biological Function of Long Non-coding RNA CDKN2BAS in Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(04):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
[10]梁燕茹,郑 瑜,李 倩.子宫内膜癌患者术前血清apo AI 和Apelin 水平检测对预测淋巴脉管间隙浸润风险的价值研究[J].现代检验医学杂志,2023,38(05):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
　LIANG Yanru,ZHENG Yu,LI Qian.Value of Preoperative Serum Apo AI and Apelin Levels in Predicting the Risk of Lymph Node Vascular Space Infiltration in Patients with Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2023,38(04):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]

备注/Memo

备注/Memo:
作者简介:李晓丽(1978-),女,本科,主治医师,研究方向:宫腔镜检查及治疗,E-mail:baolixiaol@163.com。 通讯作者:胡陇娟(1985-),女,本科,主治医师,E-mail:406943660@qq.com。收稿日期:2019-03-25 修回日期:2019-04-23
更新日期/Last Update: 2019-07-30